Pre-Revenue Startup Valuation: Berkus, Scorecard & Revenue Ramp Bayesian Methods

Why Pre-Revenue Valuation Is Different

Every valuation methodology ultimately derives enterprise value from expected future cash flows, comparable transactions, or net asset values. When a company has operating revenue — even a single quarter of recognised sales — the valuer has an anchor: multiply the revenue by a sector multiple, project growth with some empirical basis, or discount observable cash flows. Pre-revenue startups offer none of these anchors.

The fundamental challenge is threefold:

• No historical financial data to extrapolate: There are no revenue trends, no gross margin patterns, no customer acquisition cost (CAC) history, and no churn data. Any projection is built entirely on assumptions about the future.
• Extreme outcome asymmetry: Most pre-revenue startups will either fail entirely (returning zero to investors) or succeed in capturing a market opportunity worth multiples of the invested capital. The expected value is dominated by low-probability, high-payoff scenarios.
• Regulatory insistence on a specific number: Despite the inherent uncertainty, Indian tax and foreign exchange regulations require a single fair market value per share. Rule 11UA does not accept a range — the valuation report must state a price. FEMA NDI Rules require a floor price. This creates tension between intellectual honesty (the value is genuinely uncertain) and regulatory compliance (a number must be certified).

At our practice, we address this tension by using multiple pre-revenue methods, triangulating results, and documenting the rationale for the chosen value with regulatory-grade rigour. This approach has withstood scrutiny in Income Tax assessments, FEMA audits, and NCLT proceedings.

The Regulatory Framework for Pre-Revenue Valuation in India

Rule 11UA of the Income Tax Rules, 1962

Rule 11UA is the primary valuation rule for income tax purposes. It applies whenever shares are issued at a premium under Section 56(2)(viib) (formerly the angel tax provision) or when shares are transferred and the consideration needs to be benchmarked against fair value. The rule prescribes two methods for determining fair market value of unquoted equity shares:

• Rule 11UA(1)(c)(b) — Net Asset Value (NAV) Method: Fair market value equals the book value of assets minus liabilities, divided by the total number of equity shares. For pre-revenue startups with minimal assets, this method typically yields a value close to the paid-up capital — making it unsuitable for companies that have raised or seek to raise venture funding at a premium.
• Rule 11UA(1)(c)(c) — DCF Method: Fair market value is determined by discounting projected free cash flows. This is the method most commonly used by valuers for startups, but it requires revenue and cost projections that, for pre-revenue companies, are entirely assumption-driven.
• Rule 11UA(2)(b) — Merchant Banker valuation using any internationally accepted pricing methodology: This clause permits a SEBI-registered Merchant Banker to substantiate the valuation using any internationally accepted methodology. The Berkus Method, Scorecard Method, and Bayesian scenario analysis all qualify under this clause because they are recognised in venture capital and angel investing literature globally.

The Finance Act, 2023 (effective AY 2024-25) unified the valuation framework so that the same Rule 11UA applies whether shares are issued to residents or non-residents. Previously, separate pricing existed under Section 56(2)(viib) for residents and FEMA for non-residents, creating potential valuation mismatches. The unification means a single valuation report can now serve both domestic and cross-border rounds, provided it is issued by a Merchant Banker or, in certain cases, an IBBI Registered Valuer.

Additionally, the DPIIT Notification dated 19 February 2019 (as amended) exempted DPIIT-recognised startups from angel tax provisions under Section 56(2)(viib) — allowing them to issue shares at any premium to eligible investors without triggering deemed income. This exemption, which was extended through various notifications, was complemented by the broader abolition of angel tax effective from Assessment Year 2025-26 under the Finance (No. 2) Act, 2024. For a detailed analysis of the residual issues after angel tax abolition, see our article on Angel Tax Abolition: Residual Issues.

FEMA Non-Debt Instrument (NDI) Rules, 2019

When a startup issues shares to a foreign investor (FDI), pricing must comply with FEMA NDI Rules. The relevant provisions are:

• Rule 21 read with Schedule I, Para 1.1.4: Equity instruments issued to persons resident outside India must be priced at not less than the fair value determined by a SEBI-registered Merchant Banker or a practising Chartered Accountant using any internationally accepted pricing methodology on an arm’s length basis.
• DPIIT-recognised startups — Exemption: The RBI and DPIIT jointly permitted DPIIT-recognised startups to issue equity or convertible instruments to non-residents at any negotiated price, without reference to fair value, subject to conditions including a cap on investment (INR 25 crore from a single non-resident) and compliance with FEMA reporting requirements. This was operational through RBI’s AP (DIR) circulars and DPIIT’s notification.
• Post-exemption pricing: For companies that do not qualify or where the exemption has lapsed, the floor price must be supported by a valuation certificate. The valuer must use a methodology that is internationally accepted and document the arm’s length nature of the pricing. Our practice routinely issues dual-purpose reports that satisfy both Rule 11UA and FEMA NDI pricing requirements — see our FEMA valuation guide for details.

IBBI (Registered Valuers) Regulations, 2018

IBBI Registered Valuers (Securities or Financial Assets class) are authorised to issue valuation reports under the Companies Act, 2013, the Insolvency and Bankruptcy Code, 2016, and are accepted by Income Tax authorities for Rule 11UA DCF valuations. The IBBI requires registered valuers to exercise independent professional judgement, document methodology selection rationale, perform sensitivity analysis, and comply with the Valuation Standards issued by IBBI. CA V. Viswanathan (IBBI/RV/03/2019/12333) is registered under the Securities or Financial Assets class and has issued pre-revenue valuation reports that have been accepted in Income Tax scrutiny proceedings, FEMA compliance audits, and investor due diligence reviews.

Method 1: The Berkus Method

Origin and Rationale

The Berkus Method was developed by Dave Berkus, an American angel investor and venture capitalist, in the mid-1990s. It was designed specifically for pre-revenue startups where traditional financial metrics are unavailable. The core insight is that value at the pre-revenue stage is driven by risk reduction rather than financial performance. Each milestone that a startup achieves — assembling a team, building a prototype, securing a customer letter of intent — reduces a specific category of risk, and that risk reduction has quantifiable value.

The method was originally calibrated for US startups with a maximum pre-money valuation of USD 2 million (approximately INR 16 crore at current rates). In our practice, we recalibrate the maximum per-dimension value for the Indian context based on sector, geography, and the current funding environment.

The Five Risk Dimensions

The Berkus Method assigns a value of zero to a maximum cap for each of five risk dimensions. The original US framework caps each at USD 500,000; in our Indian practice, we use sector-specific caps, typically ranging from INR 1 crore to INR 4 crore per dimension depending on the addressable market size and the stage of the ecosystem.

Risk Dimension	What It Measures	Evidence Required	Typical Indian Cap (INR Cr)
Sound Idea (Basic Value)	Is the business concept addressing a real, identifiable market need?	Market research, TAM/SAM/SOM analysis, problem-solution fit documentation	1.0 – 3.0
Prototype / Technology	Has the team built a working prototype or minimum viable product?	Working demo, beta product, patent applications, technical architecture documents	1.0 – 4.0
Quality Management Team	Does the founding team have domain expertise, execution track record, and complementary skills?	Founder CVs, prior exits, domain experience, advisory board composition	1.5 – 4.0
Strategic Relationships	Has the startup secured distribution partnerships, letters of intent, or anchor customer commitments?	Signed LOIs, partnership MOUs, pilot programme agreements, channel partner commitments	0.5 – 3.0
Product Rollout / Sales	Has the product been launched or are there early (non-recurring) sales signals?	Beta user metrics, wait-list data, pre-orders, early-adopter engagement data	0.5 – 3.0

Applying the Berkus Method: Step-by-Step

Step 1 — Define sector-appropriate caps. We begin by identifying 10–15 comparable startups in the same sector and geography that raised pre-seed or seed funding in the preceding 18 months. The median pre-money valuation of these comparables sets the aggregate cap. For example, if the median pre-seed valuation for Indian B2B SaaS companies is INR 12 crore, the aggregate Berkus cap is INR 12 crore, distributed across the five dimensions based on their relative importance in that sector.

Step 2 — Score each dimension. We assign a score from 0% to 100% for each dimension based on the evidence provided by the founder and verified through our due diligence. A score of 0% means the risk is entirely unmitigated (e.g., no prototype exists). A score of 100% means the risk is fully mitigated (e.g., a working product with demonstrated technical feasibility and IP protection).

Step 3 — Calculate dimension values. Each dimension’s value equals the score multiplied by the sector-specific cap for that dimension. The sum of all five dimension values is the pre-money enterprise value.

Step 4 — Cross-validate. We cross-check the Berkus output against recent comparable transactions and, where possible, against a simplified probability-weighted DCF. If the Berkus value is more than 1.5 standard deviations from the comparable median, we re-examine and document the rationale for the deviation.

Berkus Method: Worked Example

Consider a deep-tech startup building an AI-powered quality inspection system for automotive manufacturing. The company has no revenue but has a working prototype deployed at one factory on a pilot basis. The founding team includes two IIT alumni with 15 years of combined experience in computer vision and one co-founder from the automotive industry.

Dimension	Cap (INR Cr)	Score	Value (INR Cr)
Sound Idea	2.5	85%	2.13
Prototype / Technology	3.5	75%	2.63
Quality Management Team	3.5	80%	2.80
Strategic Relationships	2.0	40%	0.80
Product Rollout / Sales	2.5	30%	0.75
Total Pre-Money Valuation			9.11

The Berkus Method yields a pre-money valuation of approximately INR 9.1 crore. This aligns with the pre-seed range for Indian deep-tech startups with working prototypes and strong teams. The relatively low scores on Strategic Relationships and Product Rollout reflect the early stage — the pilot is not yet a commercial contract, and no distribution partnerships have been formalised.

Method 2: The Scorecard Method

Origin and Framework

The Scorecard Method was developed by Bill Payne, a prominent angel investor and co-founder of the Frontier Angel Fund. It is the most widely used angel valuation method in the United States and has been adapted for international markets including India. The method’s strength lies in its comparative rigour — it benchmarks the subject startup against the median valuation of comparable recently-funded startups, then adjusts upward or downward based on qualitative factors.

Unlike the Berkus Method (which builds value additively from zero), the Scorecard Method starts from a market-derived median and adjusts. This makes it inherently market-anchored, which is an advantage for regulatory defensibility — the valuation is grounded in observable transactions rather than the valuer’s subjective assessment of maximum dimension values.

The Six Adjustment Factors

The Scorecard Method uses six weighted adjustment factors. Each factor is scored relative to the median comparable (100% = at par with median, above 100% = better than median, below 100% = worse). The weighted adjustment factors sum to produce a composite multiplier applied to the median pre-money valuation.

Factor	Weight	Assessment Criteria
Strength of Management Team	30%	Domain expertise, prior startup experience, prior exits, complementary skill sets, full-time commitment, advisory board quality
Size of Opportunity	25%	Total addressable market (TAM), serviceable addressable market (SAM), market growth rate, regulatory tailwinds or headwinds
Product / Technology	15%	Stage of development, technical differentiation, IP protection (patents, trade secrets), prototype functionality
Competitive Environment	10%	Number and strength of direct competitors, barriers to entry, network effects, switching costs
Marketing / Sales Channels	10%	Go-to-market strategy clarity, distribution partnerships secured, early customer acquisition evidence
Need for Additional Funding	5%	Expected burn rate relative to round size, runway post-funding, likelihood of needing a bridge round

A crucial nuance: the factor scores are not absolute — they are relative to the comparable set. If the median comparable startup has a two-person founding team with five years of domain experience, a target startup with three co-founders and 25 years of combined experience would score 125–140% on the Management factor. Conversely, a solo founder with no domain experience might score 60–70%.

Scorecard Method: Step-by-Step Process

Step 1 — Build the comparable set. We identify 8–12 startups in the same sector, geography (India or South Asia), and stage (pre-revenue or very early revenue) that raised equity funding in the preceding 12–18 months. Sources include Tracxn, Venture Intelligence, Inc42 deal databases, and our proprietary transaction database. We exclude outliers (top and bottom 10% by valuation) to arrive at a robust median.

Step 2 — Determine the median pre-money valuation. From the comparable set, we calculate the median pre-money valuation. For Indian SaaS pre-seed rounds in 2025–2026, this median has ranged from INR 8 crore to INR 15 crore. For D2C brands, INR 5 crore to INR 10 crore. For deep-tech (hardware + software), INR 10 crore to INR 20 crore.

Step 3 — Score each factor. We score each of the six factors relative to the median comparable. The scoring is evidence-based: we require specific documentation for each factor (founder CVs, market research reports, competitive analysis, patent applications, LOIs, financial projections for burn rate analysis).

Step 4 — Calculate the weighted composite factor. The composite factor = sum of (factor weight x factor score). For example, if the Management score is 130% at 30% weight, the contribution is 0.30 x 1.30 = 0.39. Sum all six contributions to get the composite multiplier.

Step 5 — Apply the composite multiplier to the median. Pre-money valuation = Median pre-money x Composite multiplier. If the median is INR 12 crore and the composite multiplier is 1.15, the target startup’s pre-money valuation is INR 13.8 crore.

Scorecard Method: Worked Example

Consider a fintech startup building an embedded lending platform for e-commerce marketplaces. The company has no revenue, has built an MVP integrated with one marketplace on a sandbox basis, and has a three-person founding team with experience at leading NBFCs and a prior exit.

Comparable set median pre-money valuation (Indian fintech pre-seed, 2025–2026): INR 14 crore.

Factor	Weight	Score	Weighted Contribution
Management Team	30%	135%	0.405
Size of Opportunity	25%	120%	0.300
Product / Technology	15%	110%	0.165
Competitive Environment	10%	85%	0.085
Marketing / Sales Channels	10%	90%	0.090
Need for Additional Funding	5%	100%	0.050
Composite Multiplier			1.095

Pre-money valuation = INR 14 crore x 1.095 = INR 15.33 crore.

The above-median score on Management (prior exit, NBFC experience) and Market Size (embedded lending TAM in India exceeds USD 50 billion by multiple estimates) drives the valuation above the median. The below-median score on Competitive Environment reflects the crowded fintech lending space, tempering the uplift.

Method 3: Revenue Ramp Bayesian Analysis

The Conceptual Framework

Revenue Ramp Bayesian analysis is the most quantitatively rigorous of the three methods and the one we prefer for startups raising Series A-scale pre-revenue rounds (typically INR 5 crore to INR 30 crore). It combines two powerful concepts:

• Revenue ramp modelling: Rather than projecting a single revenue trajectory, we model 3–5 distinct revenue scenarios representing different outcomes — from aggressive success to moderate traction to failure. Each scenario has a complete revenue-to-cashflow model over a 5–7 year projection horizon.
• Bayesian probability weighting: Each scenario is assigned a prior probability based on base rates (historical success rates for startups at a similar stage in a similar sector) and adjusted by the specific evidence available for the subject startup. As new information arrives (e.g., the startup signs its first customer), the probabilities are updated using Bayes’ theorem, and the valuation is recalculated.

The output is not a single number but a probability-weighted expected value. For regulatory purposes (Rule 11UA requires a single price), we report the expected value (probability-weighted mean) as the fair market value, with the full probability distribution documented in the annexures to the valuation report.

Constructing Revenue Scenarios

We typically construct four scenarios for a pre-revenue startup:

Scenario 1 — Aggressive Success (probability: 5–15%). The startup achieves product-market fit rapidly, scales revenue aggressively, and reaches a valuation exit or significant follow-on round within 3–4 years. Revenue ramp: zero to INR 50+ crore ARR in 4 years. This scenario assumes everything goes right — strong customer pull, efficient CAC, low churn, successful fundraising at each subsequent round.

Scenario 2 — Moderate Success (probability: 20–30%). The startup achieves product-market fit but takes longer to scale. Revenue ramp: zero to INR 10–20 crore ARR in 4 years. Unit economics are sound but growth is capital-constrained. The startup eventually reaches a modest exit or becomes a sustainable profitable business.

Scenario 3 — Survival / Pivot (probability: 25–35%). The initial product does not achieve strong market fit, but the team pivots to an adjacent opportunity and builds a viable but smaller business. Revenue ramp: zero to INR 2–5 crore ARR in 4 years. Investor returns are modest — capital preservation with minimal upside.

Scenario 4 — Failure (probability: 30–40%). The startup fails to achieve product-market fit, burns through its capital, and winds down. Terminal value is zero or near-zero. The probability assigned to this scenario is anchored to base-rate failure data. For Indian startups at the pre-seed stage, historical failure rates (defined as returning less than 1x capital to investors) are approximately 60–70% according to multiple angel network datasets. We adjust downward from this base rate based on the specific strengths of the subject startup.

Valuing Each Scenario

Each scenario is valued independently using a DCF methodology. For pre-revenue startups, the DCF within each scenario uses:

• Revenue projections: Specific to the scenario (see revenue ramps above).
• Cost structure: Based on the startup’s current operating plan, adjusted for the growth rate in each scenario. Higher growth scenarios assume higher sales and marketing spend, higher headcount, and higher infrastructure costs.
• Discount rate: We use a risk-adjusted discount rate of 35–50% for pre-revenue startups, reflecting the equity risk premium, size premium, and specific company risk premium. The rate is higher for earlier-stage companies and lower for companies with stronger risk mitigation (experienced team, working product, signed LOIs).
• Terminal value: Calculated using an exit multiple on Year 5 revenue, benchmarked to public market comparables in the same sector with a private company discount of 25–35%. For the failure scenario, terminal value is zero.

Bayesian Probability Assignment and Updating

The initial (prior) probabilities are assigned based on:

• Base rates: Historical success rates for startups at a similar stage, in a similar sector, in the Indian market. Sources include published reports from Indian angel networks (Indian Angel Network, Mumbai Angels, Chennai Angels), Tracxn’s startup failure/success data, and our proprietary database of 500+ valuations.
• Specific evidence adjustment: We adjust base-rate probabilities using a structured scoring framework. Positive evidence (strong team, working prototype, signed LOIs, sector tailwinds) shifts probability from the Failure scenario toward the Moderate and Aggressive Success scenarios. Negative evidence (solo founder, no prototype, crowded market, regulatory uncertainty) shifts probability toward Failure.

The Bayesian updating mechanism makes this method particularly powerful for milestone-based funding structures. When the startup achieves a specific milestone (e.g., first paying customer, regulatory approval, partnership signing), the probabilities are formally updated. The aggressive success probability increases, the failure probability decreases, and the expected enterprise value rises — justifying a higher share price for the next funding round.

Revenue Ramp Bayesian: Worked Example

Consider a healthtech startup building an AI-powered diagnostic assistance platform for radiology departments. The company has no revenue, has completed clinical validation at two hospitals, and has received CDSCO approval for its Class B medical device software. The founding team includes a radiologist and two engineers from a leading AI research lab.

Scenario	Probability	Year 5 Revenue (INR Cr)	Enterprise Value (INR Cr)	PV Today (INR Cr)
Aggressive Success	10%	80	640	142.2
Moderate Success	25%	18	108	24.0
Survival / Pivot	30%	4	16	3.6
Failure	35%	0	0	0
Expected Enterprise Value				21.4

Probability-weighted expected enterprise value = (10% x 142.2) + (25% x 24.0) + (30% x 3.6) + (35% x 0) = 14.22 + 6.00 + 1.08 + 0 = INR 21.3 crore.

Note how the valuation is dominated by the Aggressive Success scenario despite its low 10% probability — the payoff in that scenario is so large that even a small probability contributes significantly to expected value. This is a fundamental feature of venture investing and explains why angel investors and VCs accept high failure rates.

The discount rate used was 40% (reflecting pre-revenue risk, healthtech regulatory risk, and India-specific risk premiums). The Year 5 exit multiple of 8x revenue (for the Aggressive scenario) is benchmarked to public healthtech SaaS companies listed on Indian and US exchanges, adjusted for a 30% private company discount.

Triangulation: Combining Multiple Methods

At our practice, we never rely on a single pre-revenue method. Each method has inherent limitations:

• Berkus: Subjective dimension caps; no explicit link to financial outcomes.
• Scorecard: Dependent on quality and relevance of the comparable set; median-anchored bias.
• Bayesian: Scenario construction is assumption-heavy; probability assignment can be influenced by anchoring bias.

We triangulate by applying at least two methods (sometimes all three) and examining the convergence zone. If the Berkus Method yields INR 9 crore, the Scorecard Method yields INR 15 crore, and the Bayesian analysis yields INR 21 crore, we analyse the reasons for divergence and arrive at a justified point estimate within the range. The valuation report documents each method, the triangulation analysis, and the rationale for the final selected value.

For regulatory purposes, the final fair market value stated in the report is typically the value derived from the most defensible method for the specific context. For Rule 11UA compliance, we favour the Bayesian method (because it is closest in structure to DCF, which is an expressly permitted method under Rule 11UA(1)(c)(c)). For FEMA NDI pricing, all three methods are equally acceptable as they are internationally accepted pricing methodologies.

Common Pitfalls in Pre-Revenue Valuation

Pitfall 1: Using DCF Without Acknowledging Its Limitations

Many valuers default to a standard DCF model for pre-revenue startups. While DCF is technically permitted under Rule 11UA, a DCF that projects revenue from zero to INR 100 crore in five years using a single set of assumptions — without scenario analysis or probability weighting — is intellectually dishonest. The projections are not forecasts in any meaningful sense; they are aspirational targets. A rigorous valuation must acknowledge this uncertainty, either through explicit scenario analysis (as in the Bayesian method) or through wider sensitivity ranges. We have seen Income Tax officers challenge DCF-based valuations where the projected revenue growth was 200% per annum with no supporting evidence — and rightly so.

Pitfall 2: Ignoring Base-Rate Failure Probabilities

Founders and investors frequently overestimate the probability of success. Cognitive biases — optimism bias, survivorship bias, overconfidence — are well-documented in entrepreneurial decision-making. A rigorous pre-revenue valuation must anchor to base-rate failure data and then adjust. Ignoring the 60–70% base-rate failure probability for pre-seed startups produces valuations that are systematically inflated. This is not merely an academic concern — an inflated valuation certified by a registered valuer can trigger regulatory scrutiny if it subsequently appears inconsistent with the startup’s trajectory.

Pitfall 3: Confusing Pre-Money Valuation with Fair Market Value

The pre-money valuation negotiated between founders and investors is a negotiated commercial term — it reflects supply and demand for the equity, the investor’s portfolio strategy, the founder’s negotiating leverage, and non-financial terms (board seats, liquidation preferences, anti-dilution rights). Fair market value under Rule 11UA, by contrast, is an intrinsic value concept — what a willing buyer would pay a willing seller, both having reasonable knowledge of relevant facts, in an arm’s length transaction. These two concepts can diverge significantly. A startup may negotiate a pre-money valuation of INR 30 crore with a strategic investor who values synergies, while the Rule 11UA fair market value (which excludes synergies) might be INR 15 crore. The valuer must be clear about which concept is being certified.

Pitfall 4: Insufficient Documentation

Pre-revenue valuations are inherently judgemental. The valuer is making assessments about team quality, market size, technology differentiation, and competitive dynamics — none of which can be verified from financial statements. This makes documentation critical. Every assumption must be traced to a source: market research reports, founder interviews, patent filings, LOIs, competitive analysis, comparable transaction data. We maintain a documentation standard of 50+ pages of supporting evidence for each pre-revenue valuation, separate from the valuation report itself. This documentation has proven invaluable when defending valuations before Income Tax officers, FEMA auditors, and investor due diligence teams.

Pitfall 5: Not Addressing Convertible Instruments

Many pre-revenue startups raise capital through convertible instruments (convertible notes, SAFEs, CCDs, CCPs) rather than equity. The valuation of convertible instruments requires additional analysis — the conversion terms (valuation cap, discount rate, conversion trigger events) affect the fair value of both the convertible instrument and the underlying equity. For a detailed analysis, see our article on Convertible Instruments Valuation in India.

Sector-Specific Considerations

SaaS Startups

For pre-revenue SaaS startups, the key value drivers are product readiness, integration capability, early beta metrics (if available), and the founding team’s enterprise sales experience. The Berkus dimension of “Prototype / Technology” carries the highest weight because a working product with demonstrated technical capability significantly reduces technology risk. In the Bayesian framework, we model SaaS-specific metrics — projected ARR, net revenue retention, gross margin — within each scenario. The exit multiples are benchmarked to public SaaS companies (both Indian and US-listed), adjusted for India-specific factors.

Deep-Tech / Hardware Startups

Deep-tech startups (semiconductors, advanced materials, biotech, quantum computing) face longer development timelines, higher capital requirements, and regulatory approval dependencies. The Bayesian method is most appropriate because the scenario probabilities can be calibrated to regulatory approval success rates (e.g., CDSCO approval rates for medical devices, BIS certification timelines for electronic components). The discount rate for deep-tech is typically 45–55% (higher than SaaS) reflecting the longer time to revenue and the binary nature of regulatory outcomes.

D2C / Consumer Brands

Pre-revenue D2C startups are valued primarily on brand concept, founder’s brand-building track record, and early engagement signals (social media following, waitlist sign-ups, pop-up event sales). The Scorecard Method works well for D2C because there is a relatively deep comparable set of recently-funded Indian D2C brands. The key adjustment factors are product differentiation (can the product be easily replicated?), brand resonance (is there genuine consumer pull?), and unit economics assumptions (is the projected gross margin achievable given input costs and logistics?).

Fintech Startups

Pre-revenue fintech startups face a unique regulatory dimension — RBI licensing, SEBI registration, or insurance regulatory approval may be a prerequisite for generating any revenue. The Bayesian method is well-suited because regulatory approval can be modelled as a binary gate: scenarios where approval is obtained (and revenue ramp begins) versus scenarios where approval is denied (and the startup must pivot or wind down). The FEMA compliance requirements are particularly relevant for fintech startups receiving FDI, as cross-border fintech regulations are evolving rapidly.

ESOP Valuation for Pre-Revenue Startups

Pre-revenue startups frequently issue Employee Stock Option Plans (ESOPs) to attract talent. The exercise price of ESOPs must be set with reference to the fair market value of the underlying shares. Under Section 17(2)(vi) of the Income Tax Act, the perquisite value of ESOPs at the time of exercise is calculated as the difference between the fair market value on the date of exercise and the exercise price paid by the employee.

For pre-revenue startups, the fair market value of shares at the time of grant is typically low (close to face value if no external funding has occurred). This creates a tax-efficient opportunity: granting ESOPs before the first fundraise locks in a low exercise price. However, if the startup subsequently raises a round at a significant premium, the Assessing Officer may question whether the ESOP exercise price was artificially low. The valuation report supporting the ESOP exercise price must be internally consistent with any concurrent Rule 11UA valuation. For detailed ESOP valuation guidance, see our article on ESOP Valuation in India.

The Valuation Report: Structure and Regulatory Requirements

A pre-revenue valuation report issued by our practice conforms to the IBBI Valuation Standards and includes the following sections:

1. Engagement Letter and Terms of Reference: Specifying the purpose (Rule 11UA, FEMA pricing, investor due diligence, ESOP pricing), the valuation date, the standard of value (fair market value), and the scope of work.
2. Executive Summary: The concluded fair market value per share, the methodologies employed, and the key value drivers.
3. Company Overview: Business description, founding team profiles, product status, market positioning, and capital structure.
4. Industry and Market Analysis: TAM/SAM/SOM analysis, competitive landscape, regulatory environment, and sector-specific risk factors.
5. Valuation Methodology: Detailed description of each method applied (Berkus, Scorecard, Bayesian, or a combination), with the rationale for method selection.
6. Valuation Analysis: Step-by-step workings for each method, comparable transaction data, scenario models, probability assignments, DCF calculations, and sensitivity analysis.
7. Triangulation and Conclusion: Reconciliation of values from different methods, rationale for the final selected value, and the concluded fair market value per share.
8. Caveats and Limitations: Standard caveats regarding the reliance on management representations, the forward-looking nature of projections, the use of estimates, and the limitation of the report to the stated purpose.
9. Valuer’s Certification: Statement of independence, IBBI registration details, and compliance with applicable valuation standards.
10. Annexures: Supporting documentation — comparable transaction data, market research extracts, founder CVs, LOIs, patent filings, financial model workbook, and sensitivity tables.

The report is signed by CA V. Viswanathan (IBBI/RV/03/2019/12333) and carries the Virtual Auditor firm stamp. For Rule 11UA purposes, if the valuation is required to be issued by a Merchant Banker, we coordinate with our partner SEBI-registered Merchant Banker to ensure dual certification.

Pricing for Pre-Revenue Startup Valuation

Service	Scope	Fee Range (INR)
Pre-Revenue Valuation — Rule 11UA (Single Method)	Berkus or Scorecard with documentation	25,000 – 40,000
Pre-Revenue Valuation — Rule 11UA (Multi-Method)	Berkus + Scorecard + Bayesian with triangulation	45,000 – 75,000
FEMA NDI Pricing Certificate	Floor price determination for FDI round	35,000 – 60,000
Combined Rule 11UA + FEMA Valuation	Dual-purpose report for domestic and FDI pricing	55,000 – 90,000
ESOP Fair Value Certificate (Pre-Revenue)	Exercise price justification with Black-Scholes overlay	20,000 – 35,000

All fees are exclusive of GST at 18%. Turnaround time is 5–7 working days for single-method valuations and 10–12 working days for multi-method valuations with Bayesian analysis. Expedited delivery (3 working days) is available at a 50% surcharge. View detailed pricing or book a free consultation.

Frequently Asked Questions

Virtual Auditor — AI-Powered CA & IBBI Registered Valuer Firm
Valuer: V. VISWANATHAN, FCA, ACS, CFE, IBBI/RV/03/2019/12333
Chennai (HQ): G-131, Phase III, Spencer Plaza, Anna Salai, Chennai 600002
Bangalore: 7th Floor, Mahalakshmi Chambers, 29, MG Road, Bangalore 560001
Mumbai: Workafella, Goregaon West, Mumbai 400062
Phone: +91 99622 60333 | Email: support@virtualauditor.in
Book a Free Consultation